• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

New paper on the operationalization of the ATN classification scheme in preclinical AD has been published

2021-04-06News

A new article from the EPAD consortium entitled “Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort” has recently been published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.

In this article, the ATN classification was operationalized in the first 1500 participants consented in the EPAD cohort (V1500.0), a deeply phenotyped cohort of individuals who do not have dementia. CSF biomarkers were used for A and T staging, and MRI biomarkers (age-adjusted hippocampal volume) for N as they showed that t-tau is not appropriate for describing neurodegeneration in populations without dementia. The authors further examined the neuropsychological and radiological profiles of the different ATN stages, finding that cognitive dysfunction, especially in the memory domain, appears with p-tau. The authors demonstrated that bi-directional regional volumetric changes are observed in the brain of individuals early along the ATN continuum and that cerebrovascular burden increases with biomarkers positivity along the Alzheimer’s disease continuum.

Congratulations to the authors! You can read the paper here.

The ATN classification has been added for public use to the analytical database of the EPAD Longitudinal Cohort Study (LCS), hosted by our partner Aridhia. This analytical database includes all of the clinical, cognitive and biomarker measurements of recruited participants according to the EPAD LCS protocol, collected and curated according to high quality standards. EPAD has made this database open access and publicly available to the research community through the EPAD LCS Research Access Process (ERAP). To access to it, please visit the EPAD website here.

Abstract:
Background: We classified non‐demented European Prevention of Alzheimer’s Dementia (EPAD) participants through the amyloid/tau/neurodegeneration (ATN) scheme and assessed their neuropsychological and imaging profiles. Materials and methods: From 1500 EPAD participants, 312 were excluded. Cerebrospinal fluid cut‐offs of 1000 pg/mL for amyloid beta (Aß)1‐42 and 27 pg/mL for p‐tau181 were validated using Gaussian mixture models. Given strong correlation of p‐tau and t‐tau (R2 = 0.98, P < 0.001), neurodegeneration was defined by age‐adjusted hippocampal volume. Multinomial regressions were used to test whether neuropsychological tests and regional brain volumes could distinguish ATN stages. Results: Age was 65 ± 7 years, with 58% females and 38% apolipoprotein E (APOE) ε4 carriers; 57.1% were A–T–N–, 32.5% were in the Alzheimer's disease (AD) continuum, and 10.4% suspected non‐Alzheimer's pathology. Age and cerebrovascular burden progressed with biomarker positivity (P < 0.001). Cognitive dysfunction appeared with T+. Paradoxically higher regional gray matter volumes were observed in A+T–N– compared to A–T–N– (P < 0.001). Discussion: In non‐demented individuals along the AD continuum, p‐tau drives cognitive dysfunction. Memory and language domains are affected in the earliest stages.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
AD Workbench
The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
2021-03-18
EPAD_WordCloud
EPAD releases its first data and sample access bulletin
2021-03-10
Closing EPAD article published in the Alzheimer Europe magazine
2021-02-24
Alzheimer Europe launches a report on data sharing in dementia research
2021-02-23
Local actions to keep the EPAD Longitudinal Cohort data collection going
2021-02-17
Neuronet releases its Knowledge Base dashboard
2021-02-01
Latest News
  • New paper on the operationalization of the ATN classification scheme in preclinical AD has been published
    2021-04-06
  • AD Workbench
    The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
    2021-03-18
  • EPAD_WordCloud
    EPAD releases its first data and sample access bulletin
    2021-03-10
  • Closing EPAD article published in the Alzheimer Europe magazine
    2021-02-24
  • Alzheimer Europe launches a report on data sharing in dementia research
    2021-02-23
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

If you're attending #BNA2021, check out the pre-registration poster from @GregorySarah introducing the SPeAk study. Participants of this new study must have previously enrolled in the @IMI_EPAD LCS or CHARIOT Pro study at @CenDemPrevent. #biomarker #Alzheimer’s disease #dementia twitter.com/CenDemPrevent/…

reply retweet favorite
10:18 am · 2021-04-14
Twitter
EPAD
EPAD
@IMI_EPAD

Check out the last @IMI_EPAD publication on the application of the #ATN classification scheme in the first 1500 participants consented in the EPAD Longitudinal Cohort Study. ep-ad.org/2021/04/06/new… @silvia_ingala @IMI_JU @EFPIA @EU_H2020 pic.twitter.com/3HhgMcBDN0

reply retweet favorite
8:15 am · 2021-04-13
Twitter
EPAD
EPAD
@IMI_EPAD

The @IMI_EPAD Bioresource consists of over 100,000 samples consisting of blood, CSF, saliva and urine that have been collected annually from research participants throughout their participation in the Longitudinal Cohort Study. #OpenAccess ep-ad.org/2021/03/10/epa… twitter.com/IMI_EPAD/statu… pic.twitter.com/dRjuI1opFi

reply retweet favorite
7:16 am · 2021-04-12
Twitter
EPAD
EPAD
@IMI_EPAD

The ATN classification has been added for public use to the analytical database of the @IMI_EPAD Longitudinal Cohort Study, hosted by @aridhia . ⬇️ ep-ad.org/2021/04/06/new… twitter.com/IMI_EPAD/statu…

reply retweet favorite
5:56 am · 2021-04-07
Twitter
EPAD
EPAD
@IMI_EPAD

In this article, the #ATN classification was operationalized in the first 1500 participants consented in the @IMI_EPAD cohort, a deeply phenotyped cohort of individuals who do not have #dementia. ep-ad.org/2021/04/06/new…

reply retweet favorite
7:08 am · 2021-04-06
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.